drugset / Trial / NCT06239298

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

NCT06239298

Phase 1/2 Unknown 130 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.

Timeline

Start
2024-05-10
Primary completion
2026-03
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Donafenib Small molecule 0.1 g Oral
Subject Donafenib Small molecule 0.2 g Oral
Subject ZG005 Unknown Intravenous

Indications